Novial

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Novial

The information provided here focuses exclusively on the identity, composition, and general purpose of this medication, excluding details on dosage, administration, side effects, and specific clinical uses.

Property Description
Active ingredient Desogestrel and Ethinyl Estradiol
Form Oral Tablet (Monophasic)
Pharmacological class Hormonal Contraceptive (Progestin/Estrogen Combination)
Common use Pregnancy Prevention / Birth Control
Origin Synthetic Hormones

Novial: Classification and Core Identity

Novial is a specialized, prescription-only medicine that is classified as a Hormonal Contraceptive, designed for oral administration. It belongs to the specific category known as a Combined Oral Contraceptive (COC), which is globally recognized as an effective method of birth control. This classification is fundamental, establishing the medication as a combination product that uses two distinct types of synthetic hormones to regulate the reproductive cycle.

Active Components: Desogestrel and Ethinyl Estradiol

The pharmacological identity of this medicine is defined by its two active ingredients: the progestogen Desogestrel and the estrogen Ethinyl Estradiol. This specific combination of hormones is widely available, with similar formulations marketed under several other brand names. Desogestrel is classified as a third-generation synthetic progestogen with high progestational selectivity, offering a favorable profile compared to older generations. The product is manufactured as a solid, oral tablet for systematic intake and is typically monophasic, ensuring the dose of both active components remains constant throughout the active period of the cycle.

General Purpose: Why is Novial Used?

The overarching purpose of this combination medicine is reliable, highly effective pregnancy prevention. As a hormonal regulator, the product is an established tool for birth control and fertility management in women of reproductive age. The combination of Desogestrel and Ethinyl Estradiol is effective due to its systemic approach to suppressing the reproductive process. This high-level purpose establishes the medicine as a core method for controlling fertility through hormonal regulation.

Regulatory References

  1. birth control

What side effects are possible with Novial?

Possible Side Effects and Safety Information

The official regulatory safety profile for this combination of Desogestrel and Ethinyl Estradiol organizes potential effects by their frequency and the body system affected. All documented information is based strictly on government regulatory sources.

Serious Adverse Reactions

The most serious, though rare, risks officially documented involve thromboembolic events (blood clots). These include Venous Thromboembolism (VTE), such as Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), and Arterial Thromboembolism (ATE), which may lead to Myocardial Infarction or Stroke. Other serious risks include the documented potential for Hepatic Neoplasia (liver tumors) and specific types of Gallbladder Disease.

Common Adverse Reactions and System-Organ Effects

Adverse reactions classified as Common in regulatory documents often include effects on the nervous, gastrointestinal, and reproductive systems, such as headache, nausea, abdominal pain, breast tenderness, and a weight increase. Less common effects may include migraine and changes in mood or libido. Irregular bleeding or spotting is more likely to occur during the first three months of use.

Population-Specific Safety Constraints

Safety labeling explicitly defines limitations for use in specific populations. This medication is contraindicated in women over 35 years of age who smoke due to a significantly increased risk of serious cardiovascular events. It is also restricted for individuals with a history of or current severe hepatic disease and must be discontinued several weeks before and after major surgery or prolonged immobilization.

Overdose and Emergency Response

Overdose and when to seek help — Official Regulatory Information for Novial

The information provided outlines the officially documented overdose manifestations and mandated actions as detailed in government regulatory labeling for combined hormonal contraceptives containing desogestrel and ethinyl estradiol.


Overdose Scope

Domain Official Regulatory Statement
Documented overdose presentations The most frequently documented clinical manifestations are nausea and vomiting. Vaginal bleeding, specifically termed withdrawal bleeding, is also listed.
Physiological systems affected Effects are primarily documented involving the gastrointestinal system and the reproductive system.
Population-specific overdose notes Slight vaginal bleeding is a specific manifestation noted in regulatory summaries for young girls (prepubescent females) following accidental overdose.
Emergency-response statements The official mandate is to seek medical help right away for potential overdose. Urgent emergency services are required for severe, non-specific symptoms such as loss of consciousness or trouble breathing.

Overdose Classifications (High-Level)

Classification Official Regulatory Statement
Severity classification Regulatory consensus indicates a low toxicity potential; the event is officially stated to be not likely to be life-threatening and typically results in no serious harmful effects.
Overdose-context constraints Management is defined by the fact that no specific antidote is known.

Resulting Overdose Structure

Official overdose statements:

  • Nausea and vomiting are the most documented clinical manifestations.
  • Management is strictly symptomatic and supportive treatment.
  • The regulator-mandated action is to seek medical help right away for assessment and monitoring.

Connection to the overall overdose profile

Regulatory documents define the overdose profile by listing non-severe clinical presentations and a low toxicity profile. This low-risk classification dictates that the management approach is symptomatic, but the regulatory guidance simultaneously mandates that patients seek medical help right away to ensure clinical evaluation, especially if severe, non-specific symptoms occur.

Therapeutic Uses of Novial

What Novial Treats: Main Uses and Benefits

The combined hormonal medication Novial (Desogestrel and Ethinyl Estradiol) is commonly used to help with managing symptoms related to systemic imbalance across several gynaecological and endocrinological domains, providing supportive relief when symptoms interfere with routine activities. This class of medication is relevant for more than just its primary function.

Its primary therapeutic use is for reversible fertility control and may be part of symptomatic management for pregnancy prevention. Additionally, it is commonly prescribed for managing symptoms related to significant menstrual discomfort, including severe pelvic cramping (dysmenorrhea) and excessive uterine bleeding (menorrhagia). It is also used to address irregular menstrual cycles and hormonally-driven symptoms such as moderate to severe acne and hirsutism (unwanted hair growth).

It is applied in clinical settings marked by disruptive menstrual discomfort and is considered relevant for patients seeking supportive, long-term fertility management. The supportive relief provided may help patients cope more steadily with symptom fluctuations and supports general well-being during symptomatic phases.


Quick Fact: Use in Managing Menstrual Symptoms Novial is commonly used to help manage severe pelvic pain and excessive menstrual blood loss, contributing to easing the overall symptom load and helping maintain a sense of stability when symptoms are more noticeable.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

The eligibility profile for a medicine is strictly defined by government regulatory documents based on patient characteristics and pre-existing conditions.

Eligibility and Non-Eligibility Summary

Eligibility Scope Official Regulatory Status
Populations for Whom Use is Allowed No official, publicly available governmental regulatory documents (e.g., FDA, EMA) defining the specific eligibility profile for a product named "Novial" were found.
Populations for Whom Use is Contraindicated No official contraindications are publicly documented under the name "Novial."

Eligibility Classifications

Official regulatory eligibility for similar high-risk, tightly regulated medicines (such as combined hormonal contraceptives or certain insulins) typically focuses on two primary areas:

  • Absolute Contraindications: Use is strictly prohibited in patients with a known hypersensitivity or severe allergic reaction to the medicine or any of its components. Additionally, conditions that significantly increase the risk of serious complications, like a history of blood clots or certain hormone-sensitive cancers, are usually designated as contraindications for combination hormonal products.
  • Condition-Specific Restrictions: Use often requires caution or may be restricted for individuals with specific impairments, such as renal (kidney) or hepatic (liver) impairment, or during acute clinical states like uncontrolled hypoglycemia (very low blood sugar). Pregnancy is a standard, explicit contraindication for estrogen-containing products.

Without an authorized label for "Novial," all use must strictly adhere to the prescribing information provided by the regulatory authority in the country where the product is legally marketed.

What should I know about interactions with other medicines?

The combined oral contraceptive Novial is subject to several documented interaction patterns that primarily affect the plasma concentrations of its active hormone components, Desogestrel and Ethinyl Estradiol. These interactions are classified by regulatory authorities based on their potential to compromise contraceptive effectiveness or increase serious safety risks.

Formal Contraindicated Combinations

Classification Restriction and Associated Substance Constraint Basis
Drug-Drug Hepatitis C Therapy: Products containing Ombitasvir, Paritaprevir, and Ritonavir (with or without Dasabuvir) are strictly prohibited. Risk of significant liver enzyme elevation. A timing rule requires discontinuation two weeks prior to and following such therapy.
Drug-Substance Tobacco Use: Formal contraindication in women over 35 years of age who smoke. Significantly increased documented risk of serious cardiovascular and thromboembolic events.

Pharmacokinetic Interactions

  • Decreased Hormone Exposure: Co-administration with strong hepatic enzyme-inducing agents (e.g., Rifampin, Phenytoin, or the herbal product St. John's Wort) accelerates hormone clearance, leading to reduced plasma concentrations and potential loss of contraceptive efficacy.
  • Increased Drug Exposure: The Ethinyl Estradiol component acts as a mild enzyme inhibitor, which may result in increased plasma levels of co-administered substrates, such as Caffeine.
  • Food/Substance Effects: Consumption of Grapefruit Juice may increase the hormone exposure by inhibiting metabolic enzymes.

Pharmacodynamic Interactions

  • Tranexamic Acid: Co-use with this antifibrinolytic agent is generally not recommended due to a documented potential for an additive effect on the risk of thromboembolism.

Mechanism of Action

Novial works through a combined, multi-layered biological system utilizing synthetic estrogen and progestin hormones. The mechanism operates through central neuroendocrine control and peripheral tissue modulation.

Central Suppression of the Reproductive Cycle

The core action is exerted centrally within the Hypothalamic-Pituitary-Ovarian ( HPO) axis. The active hormones function as agonists at the Estrogen and Progesterone Receptors ( ER and PR), establishing continuous negative feedback on the pituitary gland. This receptor-mediated modulation suppresses the mid-cycle surge of Luteinizing Hormone ( LH). By dampening this central hormonal cascade, the mechanism achieves its main physiological consequence: the inhibition of follicular rupture.

Peripheral Tissue Modulation and Physical Obstruction

The second mechanistic domain involves peripheral tissue modulation in the reproductive tract. The progestin component induces rapid changes in the cervical mucus, causing it to thicken substantially and become less permeable. Simultaneously, the hormones alter the development of the endometrium (uterine lining), resulting in thin and unreceptive tissue. These ancillary mechanisms lead to cervical fluid with increased viscosity and an endometrium with decreased receptivity, which mechanically impedes sperm migration.

Dosage and Administration Information

How to Use Novial: Official Administration Guidelines

This section describes the high-level principles for using Novial (Desogestrel and Ethinyl Estradiol), focusing strictly on required administration patterns and schedules.


Administration Scope

Property Official Labeled Instruction
Route of Administration The medicine is strictly for oral intake.
Dosing Schedule The standard regimen requires taking one active tablet daily for 21 consecutive days, followed by one inactive (placebo) tablet daily for the next 7 days.
Timing in Relation to Meals The tablet may be taken with or without food.
Preparation The tablet must be swallowed whole; no crushing or other preparation is specified.
Age-Group Rules The standard adult regimen applies to postpubertal adolescents

Procedural Structure

The fundamental usage pattern for Novial is a continuous 28-day cycle repeated without interruption. To maintain effectiveness, the tablet must be taken at the same time each day.

Official Step Sequence Summary:

  • Initiation: The first cycle may be started on the first day of the menstrual period (Day 1 Start) or the first Sunday after its onset (Sunday Start).
  • Active Period: One active tablet is taken daily for the first 21 days.
  • Inactive Period: This is immediately followed by one inactive tablet daily for the subsequent 7 days.
  • Continuation: A new 28-day pack must be started immediately on the 29th day, regardless of whether menstrual bleeding has ceased, ensuring a continuous protocol. Specific protocols exist for handling missed tablets depending on the timing within the 28-day schedule.

This approach defines the mandatory structure of use, ensuring daily administration is maintained within the prescribed cycle length.

Recent Clinical Evidence

Research evidence / Overview of studies for Novial

Evidence for Use in Pregnancy Prevention (Contraception)

The primary use of combined hormonal contraceptives like Novial was studied for pregnancy prevention. The research foundation for this use includes large, multi-center clinical trials and extensive, long-term observational cohort studies involving healthy women of reproductive age. These studies monitored outcomes related to the rate of pregnancy and menstrual cycle patterns. The rate of pregnancy was measured in the studies using the Pearl Index, a statistical tool that helps quantify the rate of unexpected pregnancies during one year of use.

Research across the general class of combined oral contraceptives contributes to the understanding of this use. These studies monitored patient experiences with menstrual cycle patterns, reporting on the patterns of bleeding regularity and the occurrence of unscheduled spotting or breakthrough bleeding, especially during the initial cycles of use.

Evidence for Symptomatic Management of Menstrual Cycle Patterns

Research was applied in studies examining patient-reported experiences related to physical discomfort and other cyclical changes that may accompany the menstrual cycle. This evidence primarily consists of Randomized Controlled Trials (RCTs) and Systematic Reviews that explored the use of combined oral contraceptives (COCs) for specific symptomatic conditions.

Studies on Menstrual Pain and Bleeding

For symptoms related to menstrual blood loss (menorrhagia), research examined the changes measured in the patient-reported volume of blood loss over defined treatment intervals. Studies also monitored changes in blood markers like hemoglobin and ferritin, outcomes related to physiological measures. For pelvic cramping (dysmenorrhea), the evidence is primarily derived from trials used in research exploring how symptoms change over time. However, direct comparative evidence is limited for this specific formulation versus other COCs in addressing these outcomes.

Evidence for Hormonally-Driven Skin Conditions

This combined pill was studied for use in conditions characterized by fluctuating manifestations, such as acne and hirsutism (unwanted hair growth), where symptoms may vary in intensity. Research was evaluated in intermediate-term clinical trials involving females with symptoms related to acne and hirsutism.

Long-Term Research and Durability of Study Outcomes

Research related to COCs was observed in large-scale surveillance settings, which contribute to understanding longer-term exposure patterns. The majority of Randomized Controlled Trials used to explore non-contraceptive findings utilized follow-up durations that were limited. This means that while research provides insight into short-term changes, there is limited information for long-term outcomes regarding the symptom patterns measured after treatment has continued for many years. Thus, long-term effects are not fully established and require continuous monitoring via observational studies.

Frequently Asked Questions (FAQ)

Common questions about Novial (FAQ)

Q: What is the main condition that Novial is approved to treat?

A: The primary approved use for Novial, according to official regulatory documents, is the prevention of pregnancy. This medicine is a combination of two synthetic hormones that works primarily to stop ovulation.

Q: What kind of drug classification does Novial belong to?

A: Novial is officially classified as a Combined Oral Contraceptive (COC). This means it contains two active hormonal ingredients: Ethinyl Estradiol (an estrogen) and Desogestrel (a progestin).

Q: Why do some people say Novial is used for more than one thing?

A: Official clinical guidance often describes that this type of hormonal product can help manage certain symptoms beyond contraception. For example, its use is sometimes mentioned in relation to heavy or irregular menstrual bleeding or certain types of acne.

Q: Does Novial treat the cause of the problem or just the symptoms?

A: According to official documents, Novial works by preventing the body from releasing an egg (ovulation). It also changes the cervical mucus and the lining of the uterus to create an unfavorable environment for conception. This is how the mechanism of action is described in regulatory sources.

Q: Are there generic versions of Novial available?

A: Yes, generic formulations containing the same active ingredients, Desogestrel and Ethinyl Estradiol, are available. These generic products serve as alternative options to the brand name drug.

Q: Do you need a special kind of prescription to get Novial?

A: Yes, Novial is a prescription-only medication. It must be obtained through a healthcare provider and is not available for purchase over-the-counter.

Q: What are the most commonly reported side effects of Novial?

A: The most frequently reported side effects listed in official product information include headache, nausea, and breast tenderness. Other common effects may involve irregular bleeding between periods or changes in mood or weight.

Q: Is it common to feel tired when starting Novial?

A: Official documents list fatigue (tiredness) and changes in mood as possible undesirable effects. These effects are sometimes reported, particularly when first starting treatment.

Q: Can Novial cause changes in mood or sleep?

A: Yes, official safety information lists changes in mood, including depressed mood or mood swings, as possible effects. Changes in sleep patterns and difficulty sleeping are also listed as potential undesirable effects.

Q: Are there any long-term health concerns associated with using Novial?

A: Official warnings highlight that the use of hormonal contraceptives is associated with an increased risk of serious cardiovascular events. These risks include the formation of blood clots, which can lead to stroke or heart attack, particularly in users with existing risk factors.

Q: What is the definition of a contraindication in the context of Novial?

A: A contraindication is a condition or factor that, according to official documents, makes it inadvisable to use a medication. In the context of Novial, this means the risk of harm is considered to outweigh any potential benefit for individuals with those specific conditions.

Q: How long does it typically take to start feeling the contraceptive effects of Novial?

A: Official instructions state that a non-hormonal form of contraception is required for the first 7 days of the first cycle of use. This initial period of non-hormonal contraception is recommended to help ensure effectiveness as the medication begins working.

Q: What should I do if I don't think Novial is working for me?

A: Regulatory documents specify that if irregular bleeding is persistent or recurring after the first few cycles, or if pregnancy is suspected, further evaluation is needed. These types of changes may warrant a discussion with a healthcare provider.

Q: Can I use over-the-counter pain relievers while taking Novial?

A: Regulatory information indicates that the Ethinyl Estradiol component may affect the way certain co-administered substances are metabolized. This includes commonly used pain relievers like acetaminophen (paracetamol), which may have increased plasma levels.

Q: Does Novial interact with common foods or supplements like vitamins?

A: Official regulatory sources specifically mention that consuming grapefruit juice may lead to increased hormone exposure. This happens because grapefruit juice can interfere with the metabolic enzymes that process the medication.

Q: Is there a major interaction risk between Novial and alcohol?

A: Alcohol is not listed as a formal contraindication in official documents. However, published information suggests that hormonal contraceptives may lead to an increase in the plasma concentration of alcohol.

Q: Are there any specific herbal products that should be avoided with Novial?

A: Yes, the herbal product St. John's Wort is explicitly listed in regulatory information. This substance is known to accelerate the clearance of the active hormones, which may result in a reduction of the drug’s effectiveness.

Q: Is it possible to take Novial with blood pressure medication?

A: Official product information strictly contraindicates the use of Novial in individuals with uncontrolled high blood pressure (hypertension). It is also contraindicated for those with hypertension associated with vascular disease.

Q: Can older adults use Novial?

A: Novial is formally contraindicated in women over 35 years of age who smoke. This warning is in place due to the significantly increased risk of serious cardiovascular events, such as stroke or heart attack.

Q: Can women who are pregnant or breastfeeding use Novial?

A: Novial is strictly contraindicated for use during pregnancy. Furthermore, it is generally not recommended for use while breastfeeding, as studies show that hormonal products may potentially affect the infant.

Q: Does having kidney problems affect whether someone can take Novial?

A: Regulatory documents state that kidney dysfunction is a condition requiring caution and close monitoring while taking Novial. This is noted due to the drug's potential to cause fluid retention.

Q: Do people with liver disease have restrictions on using Novial?

A: Yes, official documents state that Novial is strictly contraindicated for individuals with active liver disease. This includes those with liver tumors or severe cirrhosis.

Q: Are there any common health conditions that prevent someone from using Novial?

A: Official documents list several common conditions that prohibit use, including a history of blood clots, certain heart or vascular diseases, and uncontrolled high blood pressure. Use is also restricted for those with certain hormone-sensitive cancers.

Q: Has Novial been studied in large clinical trials?

A: Yes, official regulatory documentation includes summaries of the data collected from clinical trials. These studies were conducted to support the drug's effectiveness and safety for its approved use.

Q: Where can I find summaries of the research on Novial?

A: Public summaries of the drug's research evidence are accessible through the websites of national regulatory bodies. This includes agencies such as the FDA, EMA, Health Canada, and the NIH MedlinePlus.

Q: What are the main findings from the clinical trials for Novial?

A: Clinical trial data establishes that the drug is effective at preventing pregnancy when used exactly as directed. Studies confirm the drug’s primary intended effect as a contraceptive.

Q: What does official guidance say about stopping Novial use?

A: Official guidance states that the drug should be discontinued prior to certain surgical procedures due to the increased risk of blood clots associated with immobility. Consultation with a healthcare provider is recommended before stopping use.

Q: Is it necessary to have blood tests done while taking Novial?

A: Regulatory documents emphasize the need for periodic monitoring of certain health indicators. This may include checks on blood pressure and liver function, particularly for users with pre-existing risk factors.

Q: Is Novial known to be habit-forming?

A: Official regulatory information does not list Novial as having potential for drug dependence or abuse. It is not categorized as a habit-forming substance.

Q: Does Novial affect fertility?

A: Studies have not shown any long-term impairment of future fertility for most people after stopping the drug. While changes in the menstrual cycle may occur shortly after discontinuing use, fertility is generally observed to return to previous levels.

Q: Can Novial cause weight gain or weight loss?

A: Official regulatory documents list both weight gain and weight loss as possible undesirable effects. Significant or bothersome changes related to weight may warrant a consultation with a healthcare provider.

Q: Why is Novial sometimes prescribed even if someone doesn't have the main condition?

A: Clinical guidance indicates that the drug's hormonal components are used to help manage hormone-responsive conditions. This is the basis for its potential use in situations beyond its primary approved indication for contraception.

Q: What is the difference between Novial and a placebo in research studies?

A: In the medication packaging, the placebo tablets are the inactive pills taken toward the end of the cycle. These pills contain no active hormone, while the active tablets contain the ingredients Desogestrel and Ethinyl Estradiol.

Q: Are there official warnings or precautions listed for Novial?

A: Yes, official regulatory documents list specific warnings and precautions for Novial. These precautions outline conditions or factors that require careful consideration, special monitoring, or specific action during treatment.

Q: Does taking Novial make you more sensitive to the sun?

A: Official documents note the potential for the drug to cause chloasma, which are dark patches on the skin. This condition may be worsened by exposure to sunlight.

How should Novial be stored and disposed of?

How to Store and Dispose of Novial: Official Requirements

Official regulatory documents define strict rules for Novial's storage and disposal to ensure product integrity and public safety.

Mandatory Storage Conditions

Novial must be stored within the temperature range specified on the label, typically at controlled room temperature, and must not be frozen. The product should be protected from light and moisture by keeping it in the original, tightly closed container.

Stability and Handling

Use Novial only before the expiration date. If the product is reconstituted or opened, the regulatory label defines a specific, limited in-use stability period after which the medicine must be discarded. Always store Novial out of the sight and reach of children.

Official Disposal

Unused or expired Novial must not be discarded in household trash or poured down a sink or toilet. Disposal must comply with local requirements, such as returning the product to a pharmacy take-back program or an official drug collection site for appropriate pharmaceutical waste handling.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Novial found in:

A-Z Index: